Professor Colin Dayan
Prosiectau fel Prif Ymchwiliwr
- Accelerate the route to patient benefit of new interventions to preserve beta cell function in T1D - Study Plus (01.01.2023 - 28.02.2025)
- Albiglutide versus placebo in insulin-treated subjects with new-onset Type 1 Diabetes mellitus (22.01.2015 - 31.03.2020)
- A phase 1, randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of NGM217 in adults with autoimmune diabetes (11.04.2018 - 31.03.2020)
- Beta cell preservation via antigen-specific immunotherapy in type 1 diabetes: Enhanced epidermal antigen delivery systems (01.09.2012 - 31.05.2017)
- Clinical Trial (01.12.2015 - 31.03.2020)
Prosiectau fel Cyd-Ymchwiliwr
- Phenotyping the Brecon Cohort of childhood-onset type 1 diabetes to identify those at risk of adverse long-term outcomes who may in future merit immunotherapeutic intervention at diagnosis (01.03.2016 - 31.12.2016)
- Pregnancy outcomes in women diagnosed with type 1 diabetes mellitus in childhood: A national population-based study (01.02.2017 - 30.04.2018)
- Regulation of HAS2 transcription relevant to Graves orbitopathy (GO) (01.08.2011 - 31.12.2013)
- STEADFAST: Education outcomes in young people with diabetes: Innovative engagement and governance to support public trust (04.01.2022 - 31.08.2022)
- The personal cost of health conditions in childhood (01.02.2021 - 01.10.2023)